There have been some positive reports from pilot use of the drug Gleevec (Imatinib Mesylate) in NF1 plexiform neurofibromas. Now a second pilot study of Gleevec for treatment of plexiforms has been announced and is open for recruitment at Indiana University. This is an interventional, open-label study (i.e. no placebo arm – if you participate you will receive drug). The study needs 20 patients aged 18-65. For more information on the trial including eligibility criteria for participation, click here or got to www.clinicaltrials.gov and search ‘neurofibromatosis’ for a list of all currently trials accepting those with neurofibromatosis.
New NF1 Plexiform Neurofibroma Gleevec Trial Opens
